Key information

🔎 Fund Overview

MEI Pharma, Inc. is a pharmaceutical company with a portfolio of several drug candidates that may offer novel and differentiated therapies. The Company's treasury initiative is anchored by Litecoin. The Company has discontinued the clinical development of voruciclib, while certain nonclinical activities related to its drug candidate assets continue to be conducted by it. As part of the review of strategic alternatives, the Company may consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities.